Wasatch BioLabs (WBL) is an independent biotechnology company with a disruptive approach to research and diagnostics. We are an R&D and Oxford Nanopore Technologies-certified laboratory that offers DNA and RNA sequencing services to researchers and clinical service providers. WBL’s solutions span both standard Oxford Nanopore Technologies sequencing services as well as proprietary methylation sequencing services built off of WBL’s NESSI-Seq platform, that expand the capabilities of the nanopore platform. | Wasatch BioLabs, a leading NGS sequencing service provider, harnesses advanced native-read sequencing and streamlined R&D workflows—translating breakthrough discovery into real-world outcomes.
Ultima Genomics
At Ultima Genomics, our mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. The UG 100™ sequencer replaces complex and expensive flow cells with a 200mm open wafer to unlock multiple improvements that reduce cost, increase performance, and provide a roadmap for scalability. Automated wafer handling enables 24/7 continuous operation for flexible, high throughput labs. Our ppmSeq™ technology delivers Q60 SNV accuracy useful for liquid biopsy, MRD, somatic mosaicism, and other emerging applications on the UG 100™. | At Ultima Genomics, our mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. To achieve this, we built a revolutionary new sequencing architecture that scales far beyond conventional technologies, enabling scientists to overcome the tradeoffs they face between the breadth, depth, and frequency of sequencing.
Twist Bioscience
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research. | At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and defense, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services, please visit www.twistbioscience.com.
TruDiagnostic
TruDiagnostic Most biomarkers tell you where a patient is right now. DNA methylation tells you where they’re headed and why. TruDiagnostic is a CLIA-certified epigenetics lab and research partner specializing in DNA methylation analysis for biological age, disease risk, and multi-system health performance. Founded in 2020, we’ve built one of the largest private methylation datasets in the world: 200,000+ participants, 80+ published studies, and 115+ active research collaborators – including institutions publishing in Nature Aging and peer-reviewed clinical journals. Our positioning is deliberate: science over commercialization. Every product we offer is grounded in rigorous, independently validated research. What we bring to the table for our partners: Our Epigenetic Biomarker Proxies (EBPs) predict 2,000+ protein and metabolite biomarkers directly from a blood spot. In head-to-head comparisons, these DNA Methylation derived biomarkers outperform traditional direct measurements 62% of the time, with better effect sizes and greater signal stability. Unlike point-in-time assays, methylation patterns reflect long-term biological averages, making them less susceptible to day-to-day biological noise. Our Methylation Risk Scores (MRS) predict 5- and 10-year disease risk with ~90% accuracy across cardiovascular disease, diabetes, Alzheimer’s, Parkinson’s, and cognitive decline. Unlike polygenic risk scores, MRS are modifiable — they respond to interventions, making them uniquely actionable for clinical trials, therapeutic validation, and personalized medicine applications. Our immune deconvolution platform reconstructs cell-type composition from whole blood with only a 3% error rate compared to flow cytometry, at a fraction of the cost and complexity. We collaborate across pharma, consumer health, and clinical research. Deliverables include processed IDAT files and beta values, custom aging clocks, organ-specific risk scores, cohort-level analysis reports, and intervention efficacy assessments. Our work with Olaplex on tissue-specific skin aging demonstrates how this technology extends well beyond blood. If you’re running clinical trials, building risk stratification tools, or looking for a methylation data partner with the depth to support real discovery, we’re built for that conversation.
St. Jude Children’s Research Hospital Graduate School of Biomedical Sciences
St. Jude Children’s Research Hospital is a world-class research institution dedicated to pediatric cancer and other catastrophic childhood diseases. The first and only National Cancer Institute (NCI)-designated Comprehensive Cancer Center devoted solely to children, St. Jude is also a Center of Excellence for Influenza Research and Surveillance (CEIRS), and a World Health Organization Collaborating Center for Influenza and Childhood Cancer. Our 300 faculty members work across the spectrum of basic, translational, clinical, and population science in a highly collaborative multidisciplinary environment that includes a Nobel laureate and members of the National Academy of Science and the National Academy of Medicine. St. Jude is ranked on Fortune Magazine’s “Best Workplaces in Health Care & Biopharma” and Glassdoor’s “Best Places to Work,” and is located in the heart of Memphis, Tennessee, a vibrant and friendly city at the historic American crossroads of music, trade, food, and culture. We are in pursuit of the brightest minds in biomedical sciences, individuals poised to contribute to our research progress. Other than access to top-quality scientists and mentors, as a researcher at St. Jude, you will have: # A Blend of Academic Freedom and Industrial Efficiency: Access to shared resources and facilities led by expert scientists, coupled with cutting-edge technology, accelerates research productivity. # Customized Professional and Career Growth: Experience specifically designed programs to enhance professional growth and career readiness, empowering researchers for success. # A Sense of Community: St. Jude fosters a vibrant employee community that supports a well-balanced life. A dynamic environment fosters connections and camaraderie among researchers from diverse backgrounds. # Competitive Compensation: Embark on your journey with a competitive salary, comprehensive benefits, and generous relocation assistance, reflecting our commitment to recognizing and investing in talent.
SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally.
SeqOne
SeqOne is a leading European provider of AI-powered software for next-generation sequencing (NGS) data analysis in oncology and rare diseases. Its cloud-based platform transforms complex genomic data into fast, precise, and actionable insights, supporting molecular labs in delivering life-saving diagnoses and treatments. The SeqOne Platform is CE-IVD Class C certified under HIPAA as an in vitro diagnostic medical device. Driven by the vision of personalized medicine for every patient, everywhere, SeqOne is scaling the future of genomic medicine—one lab at a time. The company has won numerous awards, including the iLab award and the ARC Cancer Foundation’s Hélène Stark prize. It has been nominated twice for the prestigious Prix Galien award. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes, and Software Club. | SeqOne is a leading European provider of AI-powered software for next-generation sequencing (NGS) data analysis in oncology and rare diseases. Its cloud-based platform transforms complex genomic data into fast, precise, and actionable insights, supporting molecular labs in delivering life-saving diagnoses and treatments. The SeqOne Platform is CE-IVD Class C certified under IVDR as an in vitro diagnostic medical device. Driven by the vision of personalized medicine for every patient, everywhere, SeqOne is scaling the future of genomic medicine—one lab at a time. The company has won numerous awards, including the iLab award and the ARC Cancer Foundation’s Hélène Stark prize. It has been nominated twice for the prestigious Prix Galien award. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes, and Software Club.
PhenX Toolkit
The PhenX (consensus measures for Phenotypes and eXposures) Toolkit is a web-based catalog of recommended measurement protocols of phenotypes and exposures suitable for inclusion in genomic, clinical, and translational research studies with human participants.
PhenoTips
> Welcome to PhenoTips! PhenoTips is the trusted digital backbone for clinical genetics programs, providing the software infrastructure to scale precision medicine from rare disease diagnosis to population-scale genomic initiatives. Deployed at leading academic health centers, hospitals, and research institutions around the world, PhenoTips empowers genetics professionals with intuitive tools for family history capture, clinical phenotyping, and genomics data management—all in one secure, interoperable platform. > PhenoTips enables clinical genetics teams to digitize and scale their workflow through: + Pedigree Drawing & Family History Intake: Capture structured, multi-generational pedigrees with dynamic tools that align with ACMG and HPO standards. + Clinical Phenotyping: Document patient phenotypes using structured HPO terminology, enabling downstream integration with genomic analysis tools and databases. + Pre-Visit Patient Questionnaires (PPQs): Collect family and personal health information prior to clinic visits, reducing in-clinic data entry time and improving diagnostic efficiency. + Cancer Risk Assessments: Complete CANRISK assessments within the platform with a few clicks saving time and reducing administrative burnout. + Integration-Ready Architecture: Built with HL7v2 and FHIR APIs, PhenoTips integrates seamlessly with major EHRs, including Epic and Cerner. > Driving Outcomes in Rare Disease, Oncology, and Preventive Genomics PhenoTips supports a range of clinical applications from diagnosing rare Mendelian disorders to mainstreaming hereditary cancer risk assessment. By equipping genetic counselors, medical geneticists, oncologists, and research coordinators with shared, centralized tools, PhenoTips increases care team collaboration and reduces time to diagnosis. Institutions using PhenoTips report significant operational gains, including reductions in manual data entry, improved patient experience through digital intake, and increased volume of cases. The platform supports initiatives focused on equitable access to genomic services and research participation through rich phenotype and family history capture. > Accelerating the Future of Genomic Medicine At PhenoTips, we believe that genetic and genomic data should be usable, actionable, and accessible to all providers, not just specialists. Our mission is to empower clinical teams to deliver genomic medicine at scale, from rare disease diagnosis to population health screening. Whether you’re building a new genetics program or modernizing an existing clinic, PhenoTips provides the technology foundation to streamline your workflow and unlock the full potential of genomic data.